2026-03-10 カリフォルニア大学アーバイン校(UCI)
＜関連情報＞
- https://news.uci.edu/2026/03/10/promising-biological-target-for-obesity-prevention-among-postmenopausal-women-identified/
- https://www.sciencedirect.com/science/article/abs/pii/S0022316626000908
Circulating Asprosin Levels and Body Weight Changes in Postmenopausal Women: Findings from the Women’s Health Initiative
Stella Ng, Bo Yang, Jie Li, Elizabeth S. Silva, JoAnn E. Manson, Lawrence S. Phillips, Alexander P. Reiner, Atul R. Chopra, Simin Liu
The Journal of Nutrition Available online: 25 February 2026
DOI:https://doi.org/10.1016/j.tjnut.2026.101441
Abstract
Background
Weight changes after menopause contribute to cardiometabolic risk, yet hormonal determinants of long-term weight trajectories remain incompletely understood. Asprosin, a fasting-induced adipokine involved in hepatic gluconeogenesis and appetite regulation, has been associated with metabolic disease, though its prospective role in affecting weight change remain unknown.
Objective
To examine whether plasma asprosin levels are directly and prospectively associated with changes in body weight and body composition among postmenopausal women.
Methods
In a case-control study of 4,020 postmenopausal women (1,987 newly occurred/incident diabetes cases and 2,033 matched controls) nested within the Women’s Health Initiative (WHI), we prospectively evaluated participants’ baseline plasma levels of asprosin in relation to three-year changes in weight, measures of central obesity, and the risk of major weight gain or loss (≥ 7% of baseline weight). Associations were examined overall and stratified by whether they developed diabetes during followup or by baseline BMI. Dual-energy X-ray absorptiometry (DXA)-derived fat and lean mass were available in a subset of participants (n = 178).
Results
In the full cohort (n = 4,020), baseline asprosin was not associated with three-year weight change or changes in central adiposity. However, among matched controls with BMI < 30 kg/m2, participants in the highest asprosin quartile gained 1.61 kg less than those in the lowest quartile (adjusted β (95% CI): -1.61 (-2.69, -0.52), p for trend < 0.01) and had lower odds of major weight gain (adjusted OR (95% CI): 0.57 (0.37, 0.88), p for trend < 0.01) and higher odds of major weight loss (adjusted OR (95% CI): 1.83 (1.10, 3.05), p for trend = 0.02).
Conclusions
In this prospective study of postmenopausal women followed for three years, baseline asprosin levels were associated with weight change in apparently healthy women without diabetes or obesity.
